Sacubitril/valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide?

被引：0
|
作者：
McMurray, John J. V. [1 ]
机构：
[1] Univ Glasgow, British Heart Fdn Cardiovasc Res Ctr, 126 Univ Pl, Glasgow G12 8TA, Lanark, Scotland
来源：
KARDIOLOGIA POLSKA | 2021年 / 79卷 / 01期
关键词：
D O I：
10.33963/KP.15744
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：104 / 105
页数：2
相关论文
共 50 条
  • [1] Sacubitril / valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide? Reply
    Lelonek, Malgorzata
    KARDIOLOGIA POLSKA, 2021, 79 (01) : 105 - 105
  • [2] Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
    Butt, Jawad H.
    Dewan, Pooja
    Jhund, Pardeep S.
    Anand, Inder S.
    Atar, Dan
    Ge, Junbo
    Desai, Akshay S.
    Echeverria, Luis E.
    Kober, Lars
    Lam, Carolyn S. P.
    Maggioni, Aldo P.
    Martinez, Felipe
    Packer, Milton
    Rouleau, Jean L.
    Sim, David
    Van Veldhuisen, Dirk J.
    Vrtovec, Bojan
    Zannad, Faiez
    Zile, Michael R.
    Gong, Jianjian
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Solomon, Scott D.
    McMurray, John J., V
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (12) : 1130 - 1143
  • [3] Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction
    Tai, Andrew
    Ambrosy, Andrew P.
    Fudim, Marat
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (03) : E5 - E6
  • [4] Sacubitril/valsartan in an experimental model of heart failure with preserved ejection fraction
    De Angelis, A.
    Cappetta, D.
    Telesca, M.
    Bellocchio, G.
    Urbanek, K.
    Berrino, L.
    CARDIOVASCULAR RESEARCH, 2022, 118 (SUPPL 1)
  • [5] Sacubitril/valsartan as a Treatment for Resistant Hypertension in Patients With Heart Failure and Preserved Ejection Fraction
    Jhund, Pardeep S.
    Alice, M.
    Pfeffer, Marc A.
    Zannad, Faiez
    Lefkowitz, Martin P.
    Shi, Victor
    Vardeny, Orly
    Solomon, Scott
    McMurray, John J.
    CIRCULATION, 2020, 142
  • [6] EFFICACY OF SACUBITRIL/VALSARTAN INMAINTENANCE HEMODIALYSIS PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
    Fu, Sha
    Wang, Xiaohong
    Song, Qirong
    Chen, Junzhe
    Tang, Ying
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I161 - I162
  • [7] Sacubitril/Valsartan in heart failure with preserved ejection fraction in women and lower-range preserved ejection fraction
    Dachs, T.
    Nagele, F.
    Rettl, R.
    Dalos, D.
    Duca, F.
    Binder-Rodriguez, C.
    Camuz-Ligios, L.
    Dusik, F.
    Seirer, B.
    Hengstenberg, C.
    Bonderman, D.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S206 - S207
  • [8] Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
    Selvaraj, Senthil
    Claggett, Brian L.
    Packer, Milton
    Zannad, Faiez
    Anand, Inder S.
    Pieske, Burkert
    Zhao, Ziqiang
    Shi, Victor C.
    Lefkowitz, Martin P.
    McMurray, John J., V
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (17):
  • [9] Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
    Jia, Ruoyu
    Ji, Ying
    Sun, Dong
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 155
  • [10] Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction
    Greene, Stephen J.
    Fonarow, Gregg C.
    EUROPEAN HEART JOURNAL, 2023, 44 (31) : 2994 - 2997
12345